Tags

Type your tag names separated by a space and hit enter

Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis.
J Bone Miner Metab 2003; 21(6):421-7JB

Abstract

Alendronate has recently been approved for the prevention and treatment of postmenopausal osteoporosis, and its efficacy has been demonstrated in many Western countries. Our present study was performed to evaluate the effect of alendronate on bone mineral density (BMD) and its tolerability in Thais. Eighty postmenopausal women with osteoporosis participated in this study. After giving informed consent, the subjects were randomly allocated either 10 mg alendronate or placebo in a double-blind fashion. All patients received a supplement of 500 mg elemental calcium daily. BMD at the lumbar spine, femoral neck, and distal forearm was measured at baseline and 6 and 12 months after treatment. Biochemical markers of bone resorption were determined at baseline and 6 months after treatment. Baseline characteristics were similar in both alendronate- and placebo-treated groups. Ten subjects discontinued the study. Of 70 subjects, 32 received 10 mg alendronate daily and the remaining subjects received placebo. At 1 year, BMD in the alendronate-treated group had increased from baseline by 9.2%, 4.6%, and 3.1% at lumbar spine, femoral neck, and distal forearm, respectively. These percentages were greater than those in controls (4.1%, 0.6%, and 1.0%, respectively). Urinary N-terminal telopeptide (NTx)-I and serum C-terminal telopeptide (CTx)-I levels decreased in both groups after 6 months of treatment. However, more reduction was demonstrated in the alendronate-treated group (71.9% vs. 28.4%, P < 0.01, and 84.7% vs. 33.1%, P < 0.01, respectively). Compliance with treatment and drug tolerability were good in both alendronate and placebo groups. We concluded that treatment with alendronate 10 mg daily for Thai postmenopausal women with osteoporosis significantly increased BMD at all skeletal sites and reduced biochemical markers of bone resorption. It was well tolerated without any serious side effects.

Authors+Show Affiliations

Department of Medicine, Ramathibodi Hospital, Mahidol University, Rama 6th Road, Bangkok, Thailand.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

14586800

Citation

Chailurkit, La-or, et al. "Effect of Alendronate On Bone Mineral Density and Bone Turnover in Thai Postmenopausal Osteoporosis." Journal of Bone and Mineral Metabolism, vol. 21, no. 6, 2003, pp. 421-7.
Chailurkit LO, Jongjaroenprasert W, Rungbunnapun S, et al. Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis. J Bone Miner Metab. 2003;21(6):421-7.
Chailurkit, L. O., Jongjaroenprasert, W., Rungbunnapun, S., Ongphiphadhanakul, B., Sae-tung, S., & Rajatanavin, R. (2003). Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis. Journal of Bone and Mineral Metabolism, 21(6), pp. 421-7.
Chailurkit LO, et al. Effect of Alendronate On Bone Mineral Density and Bone Turnover in Thai Postmenopausal Osteoporosis. J Bone Miner Metab. 2003;21(6):421-7. PubMed PMID: 14586800.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis. AU - Chailurkit,La-or, AU - Jongjaroenprasert,Wallaya, AU - Rungbunnapun,Sasithorn, AU - Ongphiphadhanakul,Boonsong, AU - Sae-tung,Sunee, AU - Rajatanavin,Rajata, PY - 2002/11/18/received PY - 2003/03/24/accepted PY - 2003/10/31/pubmed PY - 2004/7/3/medline PY - 2003/10/31/entrez SP - 421 EP - 7 JF - Journal of bone and mineral metabolism JO - J. Bone Miner. Metab. VL - 21 IS - 6 N2 - Alendronate has recently been approved for the prevention and treatment of postmenopausal osteoporosis, and its efficacy has been demonstrated in many Western countries. Our present study was performed to evaluate the effect of alendronate on bone mineral density (BMD) and its tolerability in Thais. Eighty postmenopausal women with osteoporosis participated in this study. After giving informed consent, the subjects were randomly allocated either 10 mg alendronate or placebo in a double-blind fashion. All patients received a supplement of 500 mg elemental calcium daily. BMD at the lumbar spine, femoral neck, and distal forearm was measured at baseline and 6 and 12 months after treatment. Biochemical markers of bone resorption were determined at baseline and 6 months after treatment. Baseline characteristics were similar in both alendronate- and placebo-treated groups. Ten subjects discontinued the study. Of 70 subjects, 32 received 10 mg alendronate daily and the remaining subjects received placebo. At 1 year, BMD in the alendronate-treated group had increased from baseline by 9.2%, 4.6%, and 3.1% at lumbar spine, femoral neck, and distal forearm, respectively. These percentages were greater than those in controls (4.1%, 0.6%, and 1.0%, respectively). Urinary N-terminal telopeptide (NTx)-I and serum C-terminal telopeptide (CTx)-I levels decreased in both groups after 6 months of treatment. However, more reduction was demonstrated in the alendronate-treated group (71.9% vs. 28.4%, P < 0.01, and 84.7% vs. 33.1%, P < 0.01, respectively). Compliance with treatment and drug tolerability were good in both alendronate and placebo groups. We concluded that treatment with alendronate 10 mg daily for Thai postmenopausal women with osteoporosis significantly increased BMD at all skeletal sites and reduced biochemical markers of bone resorption. It was well tolerated without any serious side effects. SN - 0914-8779 UR - https://www.unboundmedicine.com/medline/citation/14586800/Effect_of_alendronate_on_bone_mineral_density_and_bone_turnover_in_Thai_postmenopausal_osteoporosis_ L2 - https://dx.doi.org/10.1007/s00774-003-0438-2 DB - PRIME DP - Unbound Medicine ER -